Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia.

Autor: Vitiello A; Pharmaceutical Department, Clinical Pharmacologist, Usl Umbria 1, Via XIV Settembre, 06132, Perugia, Italy., La Porta R; Pathology Department, ASUR Marche, Area Vasta 1, Urbino, Italy., Trama U; Drug Policies, Campania Region, Naples, Italy., Troiano V; Pathology Department, ASUR Marche, Area Vasta 1, Urbino, Italy., Ferrara F; Pharmaceutical Department, Hospital Pharmacist Manager, Asl Napoli 3 Sud, Dell'amicizia street 22, 80035, Naples, Nola, Italy. ferrarafr@libero.it.
Jazyk: angličtina
Zdroj: Inflammopharmacology [Inflammopharmacology] 2022 Aug; Vol. 30 (4), pp. 1407-1410. Date of Electronic Publication: 2022 Mar 15.
DOI: 10.1007/s10787-022-00962-8
Abstrakt: The renin-angiotensin system (RAS) plays a crucial role and coordinates multiple body functions through its hormonal mechanism. The RAS is supported in its function by numerous peptides such as angiotensin II (Ang II), Ang IV, Ang III, angiotensin (1-7) and (1-9). The system formed by ACE2/Ang(1-7)/MASr is a regulatory pathway within the RAS system and its functions are different from those of the ACE/Ang II/AT-1r system. Recently, it has been discovered that a key role of the RAS and the ACE2/Ang(1-7)/MASr system is in inflammatory processes such as cardiac hypertrophy and heart failure. Studies are ongoing to better understand and comprehend the function of the RAS in inflammation. Recent evidence associates AT-1r antagonists with a cardioprotective, anti-inflammatory, and anti-hypertrophic role. In this in vitro study, we demonstrate the protective role of treatment (50 and 200 μM) of an AT-1r antagonist, irbesartan, on hypoxia and inflammation-induced damage in cardiomyocytes.
(© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: